Type 2 diabetes: Complications and comorbidities

Result from ONWARDS 5 trial show weekly insulin icodec plus a dosing app offers greater reductions in glycated hemoglobin than daily basal insulin analogs for type 2 diabetes.

Latent autoimmune diabetes in adults is associated with similar risks for mortality and cardiovascular disease and an increased risk for retinopathy compared with type 2 diabetes.

Novel model for risk prediction of kidney disease progression and efficacy of SGLT2 inhibition in patients with type 2 diabetes.

SGLT2 inhibitors and GLP-1 receptor agonists appear to offer the best protection against major adverse cardiovascular events in people with type 2 diabetes.

Finerenone modifies the risk for chronic kidney disease associated cardiovascular events in patients with type 2 diabetes and moderate-to-severe albuminuria, FIDELITY study findings indicate.

Different antidiabetic medications commonly used in addition to metformin for type 2 diabetes have a similar effect on kidney function.

The results of ONWARDS 2 show significantly improved glycemic control with weekly insulin icodec versus daily insulin degludec, without significantly increased hypoglycemia, in people with type 2 diabetes.

Findings from a Swedish national cohort study published in PLOS Medicine suggest that type 2 diabetes is not an important risk factor for fracture, as this risk is only “marginally” increased in people with the condition.

A health informatics system based on routine clinical data helps physicians to prioritize high-risk people with diabetes, deliver more equitable care, and manage healthcare capacity, report researchers.

Hypertension has the largest impact on mortality risk in younger people with type 2 diabetes, whereas chronic kidney disease is a greater threat for older people, shows a population-based study.

Real-world data from the UK Biobank show the value of a healthy lifestyle in people with type 2 diabetes hoping to avoid microvascular complications.

A post-hoc analysis of DAPA-CKD indicates that people taking dapagliflozin have a reduced risk for hospitalization, for causes not limited to cardiac or renal.

A meta-analysis published in The Lancet supports the use of SGLT2 inhibitors in people with chronic kidney disease, irrespective of whether they have type 2 diabetes.

Treating people with chronic kidney disease with the SGLT2 inhibitor empagliflozin significantly reduces their risk for renal disease progression or cardiovascular mortality, report the EMPA-KIDNEY investigators.

SGLT2 inhibitors are associated with a lower risk for gout than DPP-4 inhibitors, research suggests.

The use of esmolol hydrochloride in adults with diabetic foot ulcer improves wound healing and may constitute a novel treatment option, suggests research reported at the 58th EASD Annual Meeting in Stockholm, Sweden.

People taking basal insulin to treat type 2 diabetes experience a significant reduction in the risk for acute complications, which is sustained for at least 2 years after initiating use of the Freestyle Libre, say French researchers.

Study findings suggest that the presence of microvascular complications is associated with increased risk for all-cause mortality in people with type 2 diabetes hospitalized for COVID-19.

YouTube videos about diabetic foot examination are popular, but of poor quality, report UK researchers.

Combination therapy with three commonly used medications has achieved similar levels of pain relief for people with diabetic peripheral neuropathic pain in the randomized OPTION-DM trial.